{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:28:30Z","timestamp":1789579710456,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T22:15:33Z","timestamp":1531174533000},"page":"128-138.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials"],"prefix":"10.1016","volume":"80","author":[{"given":"Dee Anna","family":"Glaser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Werschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mamelok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2018.07.002_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.002_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","article-title":"Current and emerging medical therapies for primary hyperhidrosis","volume":"7","author":"Grabell","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.002_bib3","first-page":"25","article-title":"Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results","volume":"37","author":"Amir","year":"2000","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.002_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1008968401068","article-title":"The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis","volume":"8","author":"Cina","year":"1999","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.002_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2003.12.040","article-title":"US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey","volume":"51","author":"Strutton","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.07.002_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","article-title":"The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation","volume":"15","author":"Kamudoni","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.002_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jaad.2016.07.001","article-title":"The prevalence of anxiety and\u00a0depression in patients with or without hyperhidrosis (HH)","volume":"75","author":"Bahar","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.07.002_bib8","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.athoracsur.2011.01.105","article-title":"The Society of\u00a0Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis","volume":"91","author":"Cerfolio","year":"2011","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.002_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2003.12.029","article-title":"Recognition, diagnosis, and treatment of primary focal hyperhidrosis","volume":"51","author":"Hornberger","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.07.002_bib10","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1111\/j.1468-3083.2012.04630.x","article-title":"Differences between objective efficacy and perceived efficacy in patients with palmar hyperhidrosis treated with either botulinum toxin or endoscopic thoracic sympathectomy","volume":"27","author":"Alvarez","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.07.002_bib11","first-page":"392","article-title":"Understanding patient experience with hyperhidrosis: a national survey in 1,985 patients","volume":"17","author":"Glaser","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.jaad.2018.07.002_bib12","first-page":"S16","article-title":"Confirmatory psychometric evaluation of the Axillary Sweating Daily Diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity [abstract]","volume":"11","author":"Glaser","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2018.07.002_bib13","series-title":"Guidance for Industry: Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"US Food and Drug Administration (FDA)","year":"2009"},{"key":"10.1016\/j.jaad.2018.07.002_bib14","series-title":"Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance","year":"1996"},{"issue":"20","key":"10.1016\/j.jaad.2018.07.002_bib15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research\u00a0involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jaad.2018.07.002_bib16","first-page":"908","article-title":"A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee","volume":"33","author":"Solish","year":"2007","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2018.07.002_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5414\/CP201694","article-title":"Low intrinsic drug activity and dominant vehicle (placebo) effect in the topical treatment of acne vulgaris","volume":"50","author":"Chiou","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jaad.2018.07.002_bib18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00403-015-1568-9","article-title":"Evaluating clinical trial design: systematic review of randomized vehicle-controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne","volume":"307","author":"Lamel","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2018.07.002_bib19","doi-asserted-by":"crossref","unstructured":"Glaser DA, Hebert AA, Nast A, et\u00a0al. Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis. Poster presented at the 36th Fall Clinical Dermatology Conference, Las Vegas, NV, October 12-15, 2017.","DOI":"10.25251\/skin.1.supp.94"},{"issue":"2","key":"10.1016\/j.jaad.2018.07.002_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0846.2007.00282.x","article-title":"Influence of climatic conditions on antiperspirant efficacy determined at different test areas","volume":"14","author":"Brandt","year":"2008","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.jaad.2018.07.002_bib21","unstructured":"Hebert AA, Glaser D, Green L, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase 3 randomized controlled trials. Pediatr Dermatol. In press."},{"key":"10.1016\/j.jaad.2018.07.002_bib22","doi-asserted-by":"crossref","unstructured":"Pariser DM, Hebert AA, Drew J, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient reported outcomes from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Am J Clin Dermatol. 2019;80:128-138.","DOI":"10.1016\/j.jaad.2018.07.002"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218322242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:49:09Z","timestamp":1759272549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218322242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0190962218322242"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.002","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}